GLAD: Dose-Finding, Efficacy, and Safety of AZ 242 (Tesaglitazar) in Subjects With Type 2 Diabetes

Completed · Phase 2

Conditions studied: Type 2 Diabetes

In brief

This is a 12-week randomized, double-blind, multi-center, active-controlled (open-label pioglitazone) and placebo-controlled study of tesaglitazar (0.1, 0.5, 1, 2, and 3 mg) in patients with type 2 diabetes, not adequately controlled on diet and lifestyle advice alone during the run-in period. The study comprises a 2-week enrollment period, 4 week placebo single blind run in period followed by a 12-week double blind treatment period and a 3-week follow-up period

Key facts

Study ID

NCT00280865

Run by

AstraZeneca

People needed

500

Starts

2002-04-01

Expected to finish

2003-06-01

Last updated by the study team

2006-07-31

Who can join

Age: 30 and older, up to 50. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Provision of a written informed consent
• Men or women who are 30 to 80 years of age
• Female patients: postmenopausal or surgically sterile
• Diagnosed with type 2 diabetes with C-peptide levels > 0.8 ng/mL
• Treated with diet alone or treatment with a single oral antidiabetic agent or low doses of two oral antidiabetic agents

You may not qualify if…

• Type 1 diabetes
• New York Heart Association heart failure Class III or IV
• Treatment with chronic insulin
• History of hypersensitivity or intolerance to any peroxisome proliferator-activated receptor agonist (like Actos or Avandia), or to other PPAR g or PPAR a and g agonists.
• History of drug-induced myopathy or drug-induced creatine kinase elevation, liver enzyme elevations, neutropenia (low white blood cells)
• Creatinine levels above 1.2 mg/dL
• Received any investigational product in other clinical studies within 30 days
• Any clinically significant abnormality identified on physical examination, laboratory tests or electrocardiogram, which in the judgment of the investigator would compromise the patient's safety or successful participation in the clinical study

Where it is running

• Research Site — Huntsville, Alabama, United States
• Research Site — Montgomery, Alabama, United States
• Research Site — Mesa, Arizona, United States
• Research Site — Phoenix, Arizona, United States
• Research Site — Tucson, Arizona, United States
• Research Site — Alhambra, California, United States
• Research Site — Anaheim, California, United States
• Research Site — Dinuba, California, United States
• Research Site — Escondido, California, United States
• Research Site — Fresno, California, United States
• Research Site — Greenbrae, California, United States
• Research Site — Long Beach, California, United States
• Research Site — Mission Viejo, California, United States
• Research Site — Orange, California, United States
• Research Site — Sacramento, California, United States
• Research Site — San Diego, California, United States
• Research Site — Walnut Creek, California, United States
• Research Site — Stamford, Connecticut, United States
• Research Site — Waterbury, Connecticut, United States
• Research Site — Washington D.C., District of Columbia, United States
• Research Site — Brandon, Florida, United States
• Research Site — Coral Gables, Florida, United States
• Research Site — DeLand, Florida, United States
• Research Site — Gainesville, Florida, United States
• Research Site — Birmingham, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.